Please ensure Javascript is enabled for purposes of website accessibility

Branded? Generic? They're Both Doing Great!

By Brian Orelli, PhD - Updated Apr 6, 2017 at 11:30AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Teva registers strong growth on both fronts.

Which is more impressive: a 21% increase in U.S. sales of a high-margin drug or a 14% increase in U.S. sales of low-margin products? Normally the choice would be clear, but in Teva Pharmaceutical's (Nasdaq: TEVA) case, I'm going to have to go with the slower-but-still-impressive generic drug sales growth.

That's not to say the 21% increase in sales of its multiple sclerosis drug Copaxone isn't impressive; there's tough competition out there from Biogen Idec's (Nasdaq: BIIB) Avonex, Tysabri from Biogen and Elan (NYSE: ELN), Rebif from Pfizer (NYSE: PFE) and EMD Serono, and others.

But Copaxone will face generic competition at some point -- sooner rather than later if Momenta Pharmaceuticals (Nasdaq: MNTA) and Mylan (Nasdaq: MYL) have their way -- and Copaxone will soon see competition from an oral treatment for multiple sclerosis if the Food and Drug Administration approves Novartis' (NYSE: NVS) Gilenia.

Generic drugs, on the other hand, seem to provide a never-ending supply of growth. Branded drugs are constantly losing patent protection -- Teva launched nine new products in the U.S. this quarter -- and the global push to decrease health-care costs should increase the use of generics. Plus, Teva has some ability to push margins higher as it increases in size. The company expects to close on its acquisition of Ratiopharm this quarter, and I doubt it's done growing yet.

The strong quarter on both fronts pushed Teva to increase the lower end of its 2010 guidance; the company now expects adjusted earnings to come in between $4.50 and $4.60 per share. That values the company at about 11 times this year's earnings. It is not exactly a cheap generic, but it isn't all that expensive if Teva can keep up the stellar growth.

Looking for more opinions of Teva? Rick Steier and I squared off in April. Go read them and then give us your opinion in Motley Fool CAPS.

Pfizer is a Motley Fool Inside Value recommendation. Elan and Momenta Pharmaceuticals are Rule Breakers choices. Novartis is a Global Gains recommendation. Try any of our Foolish newsletters today, free for 30 days.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$50.11 (3.77%) $1.82
Novartis AG Stock Quote
Novartis AG
NVS
$85.68 (0.12%) $0.10
Elan Corporation Limited Stock Quote
Elan Corporation Limited
ELN
Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$220.99 (1.27%) $2.77
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$11.21 (1.08%) $0.12
Viatris Inc. Stock Quote
Viatris Inc.
MYL
Momenta Pharmaceuticals, Inc. Stock Quote
Momenta Pharmaceuticals, Inc.
MNTA

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.